Pfizer moved -1.7% this evening session, trading between a high of $31.11 and a low of $30.475 per share. Yesterday the stock finished at $31.19 per share, compared to an average analyst target price of $41.1.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 5.2%. Pfizer has trailing twelve months earnings per share (EPS) of 3.76, which at today's prices amounts to a price to earnings (P/E) ratio of 8.2.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of -2.09. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
|Date Reported||Revenue ($ k)||Cost of Revenue ($ k)||Gross Margins (%)||YoY Growth (%)|
At 74.2%, Pfizer's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.